WCN26-3662 CLINICAL MANAGEMENT PROTOCOL FOR CALCIPHYLAXIS TREATED WITH HUMAN AMNIOTIC-DERIVED MESENCHYMAL STEM CELLS

Read full text Summarise with VIRAT
Authors: Ningning Wang, Ming Zeng, Jingjing Wu, Baiqiao Zhao, Jiaying Hu, Qinyi Lin, Jingfeng Zhu, Zhonglan Su, W J Ji, Jie Yang, Ling Wang, Lianju Qin
+1 more Jiayin Liu
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Calciphylaxis, also known as calcific uremic arteriolopathy (CUA), is a rare cutaneous microvascular disorder predominantly affecting patients with chronic kidney disease (CKD). It clinically manifests as rapidly progressive ischemic skin necrosis and ulceration, frequently complicated by severe secondary infections and even septic shock. Skin biopsy remains the gold standard for diagnosis, and the condition carries a one-year mortality rate as high as 80%. The lack of standardized clinical protocols limits the efficacy of conventional multidisciplinary approaches.

Fields of Study & Subjects

Parathyroid Disorders and Treatments Dermatological and Skeletal Disorders Dialysis and Renal Disease Management

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104445–104445
Publication date
25 March 2026
Language
EN